Marker Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Marker Therapeutics

08/08/2025 14:59

Marker Therapeutics Inc MRKR.OQ MRKR.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

The Houston Texas-based  company is expected to report a 38.2% decrease in revenue to $723 thousand from $1.17 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Marker Therapeutics Inc is for a loss of 41 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Marker Therapeutics Inc is $8.00, about 84.6% above its last closing price of $1.23

This summary was machine generated August 8 at 13:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)